Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. The management will attend the Barclays Global Healthcare Conference on March 14-15, presenting on March 14 at 10:45 am EST in Miami Beach, FL. Additionally, the team will join the Cantor: The Future of Oncology Virtual Symposium on April 3-4 for virtual meetings and a fireside chat. Presentations and webcasts will be accessible on Zymeworks’ website.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

• Barclays Global Healthcare Conference. Zymeworks’ management will participate in one-on-one meetings on March 14-15 and present on March 14^th at 10:45 am Eastern Standard Time (EST) in Miami Beach, FL.
• Cantor: The Future of Oncology Virtual Symposium. Zymeworks’ management will participate virtually in one-on-one meetings on April 3-4 and participate in a fireside chat.

All presentations and webcasts will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005304/en/

Investor Inquiries:

Jack Spinks

Director, Investor Relations

(604) 678-1388

ir@zymeworks.com

Media Inquiries:

Diana Papove

Director, Corporate Communications

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

When will Zymeworks participate in the Barclays Global Healthcare Conference?

Zymeworks will participate in the Barclays Global Healthcare Conference on March 14-15, 2023, presenting on March 14 at 10:45 am EST.

What is Zymeworks' next event after the Barclays Conference?

After the Barclays Conference, Zymeworks will participate in the Cantor: The Future of Oncology Virtual Symposium on April 3-4, 2023.

Where can I find Zymeworks' conference presentations?

Zymeworks' conference presentations will be available on their website at http://ir.zymeworks.com/events-and-presentations.

What is Zymeworks' focus in biotechnology?

Zymeworks focuses on developing novel, multifunctional biotherapeutics, particularly for difficult-to-treat cancers and other serious diseases.

What is the ticker symbol for Zymeworks?

The ticker symbol for Zymeworks is ZYME, and it is listed on Nasdaq.